Fight to protect NIH funding and biomedical research from Trump-era cuts.

I made a commitment early on that I would tear up Trump’s budget and write a new one.

Murray reiterates her commitment to replace Trump's budget with one that protects NIH and biomedical research funding.

After Rejecting Trump’s Cuts, In Seattle, Murray Highlights NIH Funding to Protect & Strengthen Washington State’s Biomedical Research Economy - Senator Patty Murray
primary · press_release · model gpt-5.4-mini

Murray said, “I fight for policies to hold giant pharmaceutical companies accountable and lower costs for all of us,” and framed health-care affordability as a central campaign issue.

Campaign material shows Murray explicitly running on fighting for health policy goals, consistent with the promise to fight for biomedical research and NIH-related priorities.

partial same_term

Murray Highlights Lower Prescription Drug and Health Care Costs as Key Campaign Issue
secondary · model gpt-5.4-mini · confidence 58%

Murray said she was “proud to have secured several significant, bipartisan funding increases for NIH over the past few years” and said she would “do everything I can to make sure we don’t take our foot off the gas here.”

This is direct official evidence that Murray was actively working to increase NIH funding and continue championing biomedical research before and during the Trump-era threats.

partial same_term A for effort

Senator Murray Tours Allen Institute, Vows to Continue Championing U.S. and WA Leadership in Biomedical Research
secondary · model gpt-5.4-mini · confidence 91%

Murray said the Trump administration’s NIH indirect-cost cap was “illegal” and would be “nothing short of catastrophic” for lifesaving research; the release says Congress’ bipartisan Labor-HHS appropriations bill prohibits modifications to NIH indirect costs.

Murray publicly opposed a concrete Trump-era NIH cut and pointed to existing appropriations language blocking the change, showing active protection of NIH funding.

partial same_term A for effort

Senator Murray Slams Indirect Cost Rate for NIH as Massive Indiscriminate Cut, Setting Back Progress on Lifesaving Research
secondary · model gpt-5.4-mini · confidence 97%

Section 224 says indirect-cost rules “shall continue to apply to the National Institutes of Health” and Section 240 limits multiyear-award obligations; the NIH title appropriates major funding for NIH accounts, including $48.7 billion for NIH and $226 million for the Cures Act account in the enacted law.

The enacted law preserved NIH indirect-cost protections and provided substantial NIH funding, confirming concrete protection against Trump-era cuts.

delivered same_term

Consolidated Appropriations Act, 2026, Public Law 119-75
secondary · model gpt-5.4-mini · confidence 98%

Murray said that in the government funding bill Trump signed into law on Feb. 3, 2026, she secured $48.7 billion for NIH, a $415 million increase, and that the bill rejected the Trump administration’s proposal to cap indirect cost rates at 15% and other cuts to NIH.

This is the clearest official statement tying Murray’s action to an enacted result: she secured NIH funding and blocked the proposed Trump cuts.

delivered same_term A for effort

After Rejecting Trump’s Cuts, In Seattle, Murray Highlights NIH Funding to Protect & Strengthen Washington State’s Biomedical Research Economy - Senator Patty Murray
primary · model gpt-5.4-mini · confidence 99%

Under the Consolidated Appropriations Act for FY 2026, (P.L. 119-75, Division B, Title II, Sec. 224), the provisions relating to indirect costs apply to NIH awards.

NIH’s current policy page confirms that the FY 2026 appropriations law kept NIH indirect-cost protections in force, which is direct official evidence that the threatened Trump-era NIH cut was blocked and the funding framework remained intact.

delivered same_term

Reimbursement of Indirect Costs, F&A - NIH Grants Policy Statement
secondary · model gpt-5.4-mini · confidence 97%

In FY 2026, the National Institute of Biomedical Imaging and Bioengineering (NIBIB) received a budget of $440.6 million. This funding was secured under H.R.7148 - Consolidated Appropriations Act, 2026.

A current NIH institute budget page confirms the enacted FY 2026 appropriations are in effect and that NIH biomedical research funding is being carried forward under the 2026 law, consistent with Murray’s promise having been fulfilled in the same term.

delivered same_term

Budget - National Institute of Biomedical Imaging and Bioengineering
secondary · model gpt-5.4-mini · confidence 86%

Under the Consolidated Appropriations Act for FY 2026, (P.L. 119-75, Division B, Title II, Sec. 224), the provisions relating to indirect costs apply to NIH awards.

NIH’s current policy page confirms that the FY 2026 appropriations law kept NIH indirect-cost protections in force, which is direct official evidence that the threatened Trump-era NIH cut was blocked.

delivered same_term

7.4 Reimbursement of Facilities and Administrative Costs - NIH Grants Policy Statement
secondary · model gpt-5.4-mini · confidence 97%

Public Law 119-75 enacted the Consolidated Appropriations Act, 2026.

The enacted appropriations law is the operative federal record showing the NIH funding framework and indirect-cost protections were codified into law during Murray’s current Senate term.

delivered same_term

Public Law 119-75 - Consolidated Appropriations Act, 2026
secondary · model gpt-5.4-mini · confidence 98%